SWOG 1602: A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer

February 18, 2019
https://clinicaltrials.gov/ct2/results?id=NCT03091660
Cancer - Genitourinary/ Bladder, Cancer - Genitourinary/ Bladder/ Prostate/ Urothel
Principal Investigator: Ding Wang, MD
Cancer, Bladder Cancer, Phase 3, Phase III, Swog, S1602, invasive bladder cancer
Open